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Abstract
Background: Ageing increases risk of respiratory infections and impairs the response to influenza vaccination.
Pre- and probiotics offer an opportunity to modulate anti-viral defenses and the response to vaccination via
alteration of the gut microbiota. This study investigated the effect of a novel probiotic, Bifidobacterium longum
bv. infantis CCUG 52,486, combined with a prebiotic, gluco-oligosaccharide (B. longum + Gl-OS), on the response
to seasonal influenza vaccination in young and older subjects in a double-blind, randomized controlled trial,
taking into account the influence of immunosenescence markers at baseline.
Results: Vaccination resulted in a significant increase in total antibody titres, vaccine-specific IgA, IgM and IgG
and seroprotection to all three subunits of the vaccine in both young and older subjects, and in general, the
increases in young subjects were greater. There was little effect of the synbiotic, although it tended to reduce
seroconversion to the Brisbane subunit of the vaccine and the vaccine-specific IgG response in older subjects.
Immunological characterization revealed that older subjects randomized to the synbiotic had a significantly
higher number of senescent (CD28−CD57+) helper T cells at baseline compared with those randomized to the
placebo, and they also had significantly higher plasma levels of anti-CMV IgG and a greater tendency for CMV
seropositivity. Moreover, higher numbers of CD28−CD57+ helper T cells were associated with failure to seroconvert to
Brisbane, strongly suggesting that the subjects randomized to the synbiotic were already at a significant disadvantage
in terms of likely ability to respond to the vaccine compared with those randomized to the placebo.
Conclusions: Ageing was associated with marked impairment of the antibody response to influenza vaccination in
older subjects and the synbiotic failed to reverse this impairment. However, the older subjects randomized to the
synbiotic were at a significant disadvantage due to a greater degree of immunosenscence at baseline compared with
those randomized to the placebo. Thus, baseline differences in immunosenescence between the randomized groups
are likely to have influenced the outcome of the intervention, highlighting the need for detailed immunological
characterization of subjects prior to interventions.
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Background
Influenza is a major cause of death in older people and
while vaccination offers a prophylactic solution for pre-
venting infection and associated complications, immu-
nosenescence significantly impairs vaccine efficacy [1].
Potential adjuvants and dietary strategies to improve the
immune response to influenza vaccines are therefore of
interest, particularly in older people. Emerging evidence
suggests that the resident gut microbiota plays an influ-
ential role in shaping antiviral defenses and modulating
the outcome of viral infections [2], and this forms the
basis for the hypothesis that pre- and probiotics may
modulate responses to infection or vaccination.
Trials investigating the use of probiotics in prevention
of common respiratory illnesses have produced mixed
results [3], although a recent systematic review con-
cluded that they significantly reduce episodes of acute
URTI and antibiotic usage in infants and young to
middle-aged adults [4]. Response to vaccination is in-
creasingly being used as a surrogate for the response to
infection [5]. The majority of studies investigating the
impact of probiotics on responses to vaccination have
been conducted in healthy adults, and some show bor-
derline effects of probiotics on serum or salivary IgA
titres, although the clinical relevance is not clear [6].
Studies in infants and in elderly subjects, particularly
those examining the response to influenza vaccination,
are very limited, as are studies on the effects of prebiotics
on immune function [7] and vaccination [6]. Since ageing
is associated with reduced biodiversity and compromised
stability of the gut microbiota [8], as well as immunose-
nescence, older individuals may derive particular benefit
from intervention with pre- and/or probiotics.
In selecting probiotics specifically for older individuals,
Dominguez-Bello et al. [9] suggest that “the healthy old,
rather than the healthy young, are the best donors of
probiotic species for old individuals”, because they may
be better suited to colonization and establishment of a
new equilibrium within an aged microbial community.
The strain Bifidobacterium longum bv. infantis CCUG
52,486 fits this brief because it was originally isolated
from a cohort of very healthy elderly subjects (inde-
pendent life-style, free of chronic disease, and aged
90 years or over) in Italy as part of the CROWNALIFE
EU FP5 project [10], it has been demonstrated to have
particular ecological fitness and anti-pathogenic effects
in vitro [11], and it has immunomodulatory effects
which are strongly influenced by the age of the host
[12]. Furthermore, this strain has been fully genome
sequenced so that genetic traits can potentially be re-
lated to biological effects. In this study, we examine the
ability of Bifidobacterium longum bv. infantis CCUG
52,486, combined with a gluco-oligosaccharide prebiotic
(Gl-OS), to modulate the response to seasonal influenza
vaccination in a cohort of healthy young and older sub-
jects. We also examine the extent to which baseline
markers of immunosenescence influenced the outcome of
the intervention.
Results
Subject characteristics
The characteristics of the subjects recruited to the study
are described in Table 1. Of the 125 volunteers who started
the trial, 112 completed (Fig. 1). There were no differences
in baseline characteristics between treatment groups within
the young or older cohorts (data not shown).
Effect of B. longum + Gl-OS on vaccine subunit-specific
total antibody responses to seasonal influenza
vaccination
Total antibody response to the H1N1 strain
Vaccination resulted in a significant increase in anti-
bodies to H1N1 in both young and older subjects, but
the increase was greater in the young subjects (Fig. 2a).
When the young and older cohorts were combined,
there was a trend for a treatment effect (p < 0.02;
Fig. 2a), but this did not remain when the cohorts were
analysed separately.
Total antibody response to the H3N2 strain
Vaccination resulted in a significant increase in mean anti-
body titres to the H3N2 subunit of the vaccine (Fig. 2b).
However, there was a significant age*time interaction (p <
0.01) reflecting the greater increase in antibody titres in
response to vaccination in young subjects compared to
Table 1 Baseline characteristics of subjects recruited to a
double-blind, placebo-controlled, randomised study of
Bifidobacterium longum bv. infantis CCUG 52,486 combined
with gluco-oligosaccharide
Older cohort Younger cohort
(n = 63) (n = 62)
Gender 18♂45♀ 23♂39♀
Smoker 4/63 13/62
mean (SD)
Age 69 (5) 26 (4)
BMI (kg/m2) 27 (3) 23 (3)
Waist (cm) 94 (16) 80 (9)
Weight (kg) 74 (13) 68 (13)
Height (m) 1.7 (0.1) 1.7 (0.1)
BP systolic (mmHg) 138 (17) 122 (11)
BP diastolic (mmHg) 78 (9) 74 (8)
Pulse (bpm) 70 (11) 76 (10)
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older subjects. There was no significant effect of treatment
with the synbiotic on antibody titres to H3N2 (Fig. 2b).
Total antibody response to the Brisbane strain
Vaccination increased mean antibody titres to the Brisbane
strain (Fig. 2c). There was a significant effect of age (p <
0.01), with mean antibody titres to the Brisbane subunit
being significantly higher in young subjects after vac-
cination (Fig. 2c), and there was a significant age*time
interaction, reflecting the greater response to vaccin-
ation in the young subjects (Fig. 2c).
There was no overall effect of treatment when the
young and older cohorts were combined, but when they
were considered separately, the synbiotic was associated
with a borderline effect (reduction) on the antibody
response to vaccine in the young subjects (Fig. 2c).
Effect of B. longum + Gl-OS on seroprotection to seasonal
influenza vaccination
Baseline seroprotection to H1N1 was significantly differ-
ent in the young and older subjects (Table 2). The young
subjects already had a significant level of protection at
baseline (GMT> 32) compared to older subjects, and this
was apparent in both the placebo and the synbiotic groups
(Table 2). After vaccination, seroprotection to the H1N1
strain tended to remain higher amongst the young sub-
jects compared with the older subjects (Table 2), but there
was no clear effect of treatment. There were no differ-
ences in seroprotection to H3N2 between cohorts and no
effect of the synbiotic on seroprotection to H1N1 or
H3N2 in either cohort (Table 2).
For the Brisbane strain, seroprotection was significantly
greater in the young subjects following vaccination
(Table 2), but there was no clear effect of treatment with
the synbiotic.
Effect of B. longum + Gl-OS on seroconversion to seasonal
influenza vaccination
Seroconversion to H1N1 and H3N2 was not significantly
different between the young and older subjects, although
there was a trend for better seroconversion to H3N2 in
the young subjects (Table 3). Young subjects demon-
strated significantly greater seroconversion to the Brisbane
strain than older subjects (Table 3). There was no signifi-
cant effect of supplementation with the synbiotic on sero-
conversion to Brisbane, although it tended to reduce
seroconversion in the older subjects (Table 3).
Fig. 1 Recruitment flow diagram
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Effect of B. longum + Gl-OS on levels of vaccine-specific
IgA, IgG1, IgD and IgM and salivary sIgA following
seasonal influenza vaccination
Levels of vaccine-specific IgA, IgG, IgD and IgM were
significantly increased following influenza vaccination
in both young and older subjects (Additional file 1:
Figure S1). In all cases, except for IgM, increases were
significantly greater in the young subjects (Additional
file 1: Figure S1). There was no effect of the synbiotic
on levels of vaccine-specific Ig subclasses, although
Fig. 2 Effect of B. longum + GI-OS on antibody responses to the influenza vaccine in young and older subjects. Data are log2 transformed geometric
mean antibody titres (GMT) (±2SEM) at baseline and weeks 6 and 8 for n = 54–58 subjects per group.□ Maltodextrin, B. longum+Gl-OS. The
reference line at the Y axis indicates seroprotection (GMT = 32). Data were analysed using a Linear Mixed Model (LMM) with fixed factors of time, age
and treatment. a H1N1; For the LMM, there were significant effects of age (p < 0.001) and time (p < 0.001) and a trend for a treatment effect (p < 0.02).
For data split by cohorts, there was a significant effect of time in both cohorts (p < 0.001), but no significant effect of treatment. b H3N2; for the LMM
overall, there was a significant effect of time (p < 0.001) and an age*time interaction (p < 0.01). For data split by cohort there was a significant effect of
time (p < 0.001) and a time*treatment interaction (p < 0.01) in the older cohort, and a significant effect of time (p < 0.001) in the young
cohort. c Brisbane; for the LMM overall, there were significant effects of age (p < 0.005), time (p < 0.001) and an age*time interaction (p < 0.001). For
data split by cohort, there was a significant effect of time (p < 0.001) and a time*treatment interaction (p < 0.01) in the older cohort, and a significant
effect of time (p < 0.001) in the young cohort. There was a borderline effect of treatment (p < 0.05)
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there was a tendency for a smaller IgG response in the
older subjects on the synbiotic relative to the placebo
group (p = 0.03; Additional file 1: Figure S1) and an im-
proved induction of vaccine-specific IgM and, to some de-
gree, IgG (only at week 6) in young subjects (Additional
file 1: Figure S1). There was no effect of either age or of
the synbiotic on concentrations of salivary sIgA at any
timepoint (data not shown).
Effect of B. longum + Gl-OS on copy number of B. longum
in faecal samples and influence of numbers of bifidobacteria
on seroconversion
There was a significant increase in copy numbers of B.
longum in faecal samples from subjects taking the syn-
biotic when the young and older cohorts were com-
bined (p < 0.01), but although trends remained when
the cohorts were analysed separately, they were not sta-
tistically significant (Additional file 2: Figure S2). Over-
all, no significant genus-level changes in the faecal gut
microbiota, as assessed by FISH, were observed (data
not shown), but seroconverters to all three subunits of
the influenza vaccine tended to demonstrate a greater
bifidogenic effect of the pre- and probiotic treatment
compared with non-seroconverters (p = 0.057), suggest-
ing that successful seroconversion may be associated
with increased numbers of bifidobacteria (Additional
file 3: Figure S3).
Influence of baseline markers of immunosenescence and
CMV status on intervention outcome
Older subjects randomized to the synbiotic had a sig-
nificantly higher number of senescent (CD28−CD57+)
helper T cells at baseline compared with those random-
ized to the placebo (Fig. 3). They also had significantly
higher plasma levels of anti-CMV IgG (Fig. 4) and a
greater tendency for CMV seropositivity (66.7 % vs
38.1 %). CD28−CD57+ helper T cells and cytotoxic T
cells were significantly higher in CMV+ subjects com-
pared with age-matched CMV− subjects and were posi-
tively correlated with the plasma level of anti-CMV IgG
and with telomere length (data not shown). Higher
numbers of these CD28−CD57+ helper T cells were as-
sociated with failure to seroconvert to Brisbane (Fig. 5),
suggesting that differences in immunosenescence be-
tween the randomized groups at baseline may have
influenced the outcome of the intervention.
Discussion
This paper demonstrates marked impairment of the anti-
body response to influenza vaccination in older subjects.
Intervention with a novel synbiotic, B. longum +Gl-OS
Table 3 Effect of B. longum + Gl-OS on seroconversion in young and older subjects 4 weeks after influenza vaccination (week 8)
Seroconversion status (≥ fourfold increase in Ab titres)
Vaccine strain Young cohort (n = 58) Older cohort (n = 54) p
Placebo B. longum + Gl-OS Placebo B. longum+ Gl-OS
n/N (%) n/N (%) n/N (%) n/N (%)
A/California/7/2009 (H1N1) 15/29 (52) 18/29 (62) 21/27 (78) 15/26 (58) NS
A/Perth/16/2009 (H3N2) 20/29 (69) 22/29 (76)a 17/27 (63) 10/26 (38) 0.031
B/Brisbane/60/2008 23/29 (79)a 20/29 (69)a 7/27 (26) 1/26 (4) < 0.001
Data are numbers of seroconverted (n)/total (N) and % seroconverted subjects in parentheses. P refers to results of Fisher’s exact test for differences between the
cohorts with treatment groups combined; ayoung cohort significantly different from the older cohort within same treatment group (p < 0.01, Fisher’s Exact test)
Table 2 Effect of B. longum + Gl-OS on seroprotection status in young and older subjects before and 4 weeks after influenza vaccination
Seroprotection status
Vaccine strain Young cohort (n = 58) Older cohort (n = 54) p
Placebo B. longum + Gl-OS Placebo B. longum + Gl-OS
n/N (%) n/N (%) n/N (%) n/N (%)
A/California/7/2009 (H1N1) Before 20/29 (69)a 13/29 (45)a 5/28 (18) 1/26 (4) < 0.001
After 29/29 (100) 27/29 (93)a 22/27 (81) 16/26 (62) < 0.001
A/Perth/16/2009 (H3N2) Before 10/29 (34) 13/29 (45) 8/28 (29) 12/26 (46) NS
After 26/29 (90) 27/29 (93) 25/27 (93) 22/26 (85) NS
B/Brisbane/60/2008 Before 4/29 (14) 0/29 (0) 4/24 (17) 5/26 (19) NS
After 28/29 (97) 20/29 (76) 14/27 (52) 11/26 (42) < 0.001
Data are numbers of seroprotected (n)/total (N) and % seroprotected subjects in parentheses. ‘Before’ refers to week 4 samples and ‘After’ refers to week 8
samples (ie 4 weeks after vaccination). P refers to results of Fisher’s exact test for differences between the cohorts with treatment groups combined;
ayoung cohort significantly different from the older cohort within same treatment group (p < 0.01, Fisher’s Exact test)
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failed to reverse this impairment in older subjects, and in
fact there were trends for reduced seroconversion to the
Brisbane subunit and a reduced IgG response. However,
further immunological characterization revealed a greater
degree of immunosenescence at baseline in older sub-
jects randomized to the synbiotic, which could explain
the particularly poor response of these subjects to the
vaccination. This demonstrates, for the first time, that
the interpretation of interventions examining the re-
sponse to vaccination in older people may be highly
dependent on their baseline immunological phenotype.
While there is general consensus that ageing impairs
the response to influenza vaccination [13], there are very
few robust studies specifically comparing responses of
young and older subjects, and the most comprehensive
information available is from a meta-analysis published
in 2006, which concluded that clinical vaccine efficacy in
older subjects was only 17–53 % compared with 70–
90 % in young subjects [14]. In the current study, anti-
body responses to all three subunits of the influenza
vaccine were impaired in the older subjects and there
was significantly greater seroprotection to the H1N1 and
Brisbane subunits and seroconversion to the H3N2 and
Brisbane subunits in the young subjects after vaccin-
ation. Accounting for differences in baseline seroprotec-
tion between individuals and groups was a particular
challenge in the current study since the B/Brisbane/60/
2008 strain had previously been used in the trivalent
Fig. 3 Numbers of CD28−CD57+ helper T cells at baseline differ in
older subjects randomized to B. longum + Gl-OS and placebo. Data are
absolute numbers of T-cell subsets × 1000/ml ± 2SEM for n = 58 young
and n = 54 older subjects randomized to B. longum + Gl-OS ■ or
placebo□. Data were analysed using Student’s independent t-tests
for differences between young and older subjects. ** Denotes
significant difference between treatment groups within age
cohort (p < 0.01)
Fig. 5 Lower numbers of circulating CD28-CD57+ T helper cells in
seroconverters to the Brisbane subunit compared with non-converters
amongst subjects randomized to B. longum + Gl-OS. Data are absolute
numbers of T cell subset x1000/ml ± 2SE for n = 58 young and
n = 54 older subjects. * Denotes significantly different from
non-seroconverters (P < 0.05, independent values T-test)
Fig. 4 Baseline levels of anti-CMV IgG differ in older subjects
randomized to B. longum + Gl-OS and placebo. Data are anti-CMV
IgG (AU/ml) ± 2SEM for n = 45 young and n = 45 older subjects
randomized to B. longum + Gl-OS or placebo. Data were analysed
using Student’s independent t-tests for differences between young
and older subjects. * Denotes significant difference between treatment
groups within age cohort (p < 0.05)
Przemska-Kosicka et al. Immunity & Ageing  (2016) 13:6 Page 6 of 12
vaccine in the 2009/2010 season and the H1N1 strain
had previously been used in the monovalent swine flu
vaccination during the pandemic of 2009/2010 (although
only three subjects had previously been vaccinated with
this). In the current study, individuals who were sero-
protected at baseline were not excluded because it was
considered valuable to employ a ‘real life’ scenario.
Notably, the older subjects had high pre-vaccination
antibody titres to the Brisbane strain and a poor sero-
conversion rate compared with the young subjects. On
the other hand, baseline seroprotection for the H1N1
strain was greater in the young cohort, yet rates of sero-
conversion were similar in the two cohorts.
To date, studies which have examined the potential ad-
juvant properties of probiotics given in conjunction with
influenza vaccines in healthy adults have shown promise
in their ability to beneficially modulate the humoral re-
sponse to influenza, but robust data is still lacking [6, 15].
The effects of probiotics on the response to influenza vac-
cination in older adults is of particular importance, given
the consequences of respiratory infections in older people
[16]. Among free-living Chilean subjects over 70 years old,
a complete nutritional formula containing a range of nu-
trients and vitamins plus the probiotic Lactobacillus para-
casei (NCC 2461) and the prebiotic fructo-oligosaccharide
was associated with a significantly lower incidence of
respiratory infection, but had no effect on antibody re-
sponses to vaccination [17]. Provision of a probiotic
drink containing Lactobacillus paracasei ssp. paracasei
(Actimel®) to healthy elderly volunteers (> 70 years) re-
sulted in higher influenza virus-specific antibody titres
post-vaccination, although these differences were only
statistically significant within the confirmatory phase
of this study [18]. A small study of 27 elderly (mean
age > 85) subjects provided with Bifidobacterium
longum BB536, reported significantly lower incidence
of influenza and fever in the probiotic group [19].
However, the largest study to date investigated the ef-
fect of Lactobacillus casei Shirota (LcS) on the suscep-
tibility to respiratory symptoms and influenza
vaccination responses among 737 nursing home resi-
dents (mean age > 80 year) and reported no significant
differences in antibody titres, seroconversion or sero-
protection 4 and 22 weeks after vaccination, and no ef-
fect on reported respiratory symptoms [20]. Thus the
evidence is not clear cut and it is possible that there
are differences in the immunomodulatory potential of
different strains.
In the current study, the response of the young and
older subjects to the intervention differed to some de-
gree. In older subjects consuming the synbiotic, there
was a trend for reduced seroconversion to the Brisbane
subunit, whereas in the young subjects, there were
trends for enhanced production of vaccine-specific IgM
and, to some extent, IgG. Increased production of
vaccine-specific IgM and IgG following intervention
with probiotics has been reported in several other stud-
ies [21–25]. The possibility that there is a differential im-
mune response to probiotics in young vs older subjects
has also been explored to some extent. You et al. [12]
demonstrated that peripheral blood mononuclear cells
(PBMC) from older subjects (60–85y) were more re-
sponsive to the immunoregulatory effects (IL-10 induc-
tion) of two strains of bifidobacteria than young
subjects (18–30y), whereas PBMC from young subjects
were more responsive to the immunostimulatory effects
(IL-12 induction) of two strains of lactobacilli. Further
studies demonstrated that probiotics (including the
strain employed in the current study) increased the re-
sponsiveness of DCs in older subjects to a greater de-
gree than young subjects, but this was not sufficient to
overcome the impact of immunosenescence in a mixed
leukocyte reaction [26]. The choice of probiotic, par-
ticularly for older individuals, is a matter of debate and
it has been suggested that ‘successfully aged’ donors of
probiotic strains might survive better in an older host
and achieve a more suitable equilibrium with the resi-
dent microbiota [9]. Bifidobacterium longum bv. infan-
tis CCUG 52,486 is an example of a strain present in
particularly healthy subjects aged > 90y, which has sub-
sequently been demonstrated to have particular eco-
logical fitness and anti-pathogenic effects in vitro [27]
and immunomodulatory effects which are strongly in-
fluenced by the age of the host [12, 26]. The effects of
prebiotics on immune function are less well character-
ized than those of probiotics, but are suggested to be
mainly indirect via modulation of the gut microbiota.
In the current study, the prebiotic Gl-OS was used
chiefly to support the colonization of the probiotic, and
although an independent effect of the prebiotic on the
gut microbiota cannot be excluded, the fact that the
intervention increased copy numbers of B. longum
while having no significant effect on the fecal micro-
biota at genus level suggests that the prebiotic was se-
lectively supporting the growth of the probiotic strain
in vivo.
The results of the intervention must take into account
the potential influence of baseline differences in immu-
nosenescence, which in the current study were revealed
after the study was completed and occurred entirely by
chance. T cells are particularly susceptible to senescence,
resulting in loss of CD28; repeated antigenic exposure,
for example to cytomegalovirus (CMV), is suggested to
play a major role in this [28, 29]. Latent infection with
CMV has been demonstrated to result in a poor re-
sponse to infection and vaccination [29]. In the current
study, not only did older subjects randomized to the
synbiotic have a significantly higher number of senescent
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(CD28−CD57+) helper T cells at baseline compared with
those randomized to the placebo, they also had signifi-
cantly higher plasma levels of anti-CMV IgG and a
greater tendency for CMV seropositivity. Moreover,
higher numbers of CD28−CD57+ helper T cells were as-
sociated with failure to seroconvert to Brisbane, strongly
suggesting that the subjects randomized to the synbiotic
were already at a significant disadvantage in terms of
likely ability to respond to the vaccine compared with
those randomized to the placebo and that differences in
immunosenescence between the randomized groups at
baseline may have influenced the outcome of the inter-
vention. Future work therefore needs to consider pro-
spective randomization of subjects based on robust
immunological markers; this is challenging given the
wide range of potential markers and uncertainty regard-
ing their predictive value.
In this paper, we report the effects of the synbiotic on
the humoral arm of the immune response only. How-
ever, recognizing the importance of the T cell response
following vaccination, and the potential effects of the
synbiotic on adaptive immunity [30], we conducted ex-
tensive analysis of antigen-specific T cell activation fol-
lowing in vitro vaccine recall challenge. We observed
that while the synbiotic increased the responsiveness of
cytotoxic T cells to re-stimulation with the vaccine in
young subjects, it decreased responsiveness in the older
subjects (unpublished data). Thus, the impact of greater
immunosenescence in the older subjects randomized to
the synbiotic group appears to be significant, extending
beyond the humoral arm of the immune response and
influencing the T cell response to the vaccine.
Conclusion
In conclusion, we demonstrate marked impairment of
the antibody response to influenza vaccination in older
subjects and failure of the synbiotic to reverse this im-
pairment. However, the older subjects randomized to
the synbiotic were revealed to be at a significant disad-
vantage due to significantly higher numbers of senescent
(CD28−CD57+) helper T cells at baseline compared with
those randomized to the placebo, as well as significantly
higher plasma levels of anti-CMV IgG and a greater ten-
dency for CMV seropositivity. Thus, baseline differences
in immunosenescence between the randomized groups
are likely to have influenced the outcome of the interven-
tion, highlighting the need for detailed immunological
characterization of subjects prior to interventions.
Methods
Ethics and trial registration
The study protocol was reviewed and approved by the
University of Reading Research Ethics Committee
(project number: 10/09) the National Health Service
(NHS) Research Ethics Committee for Wales (10/
MRE09/5). The trial was registered with clinicaltrials.gov
(Identifier: NCT01066377) and conducted according to
the guidelines laid down in the Declaration of Helsinki.
Participants
Prior to the influenza season of 2010–2011, young (18–
35 y) and older (60–85 y) healthy adults were recruited
from the population in and around Reading (UK)
through newspaper and poster advertisements, email
and radio. Inclusion criteria were: a signed consent form,
age 18–35 y or 60–85 y, body mass index (BMI) 18.5–
30 kg/m2, good general health, as determined by medical
questionnaires and laboratory data from screening blood
and urine sample (fasting glucose, erythrocyte sedimen-
tation rate, full blood count, liver function tests, renal
profile, dipstick urinalysis), not pregnant, lactating or
planning a pregnancy. Exclusion criteria included: allergy
to the influenza vaccine, HIV infection, diabetes requir-
ing any medication, asplenia and other acquired or con-
genital immunodeficiences, any autoimmune disease,
including connective tissue diseases, malignancy, cir-
rhosis, connective tissue diseases, current use of immu-
nomodulating medication (including oral and inhaled
steroids), self–reported symptoms of acute or recent
infection (including use of antibiotics within last
3 months), taking lactulose or any other treatment for
constipation, alcoholism and drug misuse. Additional ex-
clusion criteria for older volunteers included: laboratory
data which were outside the normal range for this age
group AND outside the ranges specified in the SENIEUR
protocol [31], Barthel Index score of < 16/100, cumulative
illness rating scale (CIRS) score of > 15 [32]. Additional
exclusion criteria for the young subjects included labora-
tory data which were outside the normal range and influ-
enza vaccination in the previous 12 months.
Sample size
The primary outcome of the trial was the antibody
response to vaccination, incorporating mean antibody ti-
tres, vaccine-specific Ig subclasses and seroprotection
and seroconversion. Power calculations were based on
mean antibody titres. Since the influenza vaccine is triva-
lent, it is unlikely that an intervention will alter the re-
sponse to all three subunits in the same way. For
example, in the study of Davidson et al. [33], there was
no effect of probiotic on mean antibody titres in re-
sponse to the H1N1 subunit, whereas the responses to
both H3N2 and the B subunit were improved (72 vs 51
[SD 16.5] for H3N2 and 31 vs 25 [SD 7.1] for B subunit).
Based on the smaller effect size for the B subunit, a sam-
ple size of 26 subjects per group within each cohort was
determined to be sufficient for a two-tailed significance
level of 5 % and a power of 80 %; this was adjusted to 30
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subjects per group to allow for dropouts. Data on the
co-primary endpoints, immunoglobulin subclasses, sero-
protection and seroconversion, is very sparse, but a sam-
ple size of 26 subjects per group within each cohort was
determined to be sufficient for a 376 mg/dL difference
in circulating IgG levels in response to influenza vac-
cination, with an SD of 438 mg/dL, a two-tailed signifi-
cance level of 5 % and a power of 80 % [23]. A total of
62 young subjects and 63 older subjects entered the
study and 58 young and 54 older subjects completed
the study (Fig. 1). Two subjects experienced adverse ef-
fects (gastrointestinal bloating) during the study, one
on the placebo group and one in the B. longum + Gl-OS
group; both withdrew from the study.
Study design
Subjects consumed Bifidobacterium longum bv. infantis
CCUG 52,486 (B. longum, 109 CFU in 1 g skim milk
powder/day) combined with gluco-oligosaccharide (Gl-
OS (BioEcolians, Solabia); 8 g/day) in a double-blind,
placebo controlled randomised parallel study design for
8 weeks. The synbiotic approach was selected because in
vitro data examining the growth and survival of this
strain indicated that it was very vulnerable compared
with other strains, but survived much better in the pres-
ence of an oligosaccharide substrate (data not shown).
When comparing a number of possible substrates, the
low water activity of Gl-OS, combined with its ability to
support the growth of the probiotic strain, made it a
clear choice for a powdered product. This prebiotic also
has bifidogenic effects in batch culture models [34]. The
placebo used was maltodextrin (9 g/day); both the pla-
cebo and the pre- and probiotic were sourced, packaged
and blinded by BioAgro S.A. (Italy). The powders were
consumed sprinkled into water or milk or with breakfast
cereal. Microbiological safety of the product was inde-
pendently verified by Leatherhead Food Research associ-
ates (UK) prior to commencement of the study and
viability of the probiotic strain was confirmed on
random samples on a weekly basis during the study.
During the 3 weeks prior to the study and during the
intervention itself, subjects were requested not to con-
sume fermented products such as yogurts, kefir etc. or
pre- or probiotic products. Dietary records were used to
confirm avoidance of such foods. Subjects were random-
ized by a research nurse not involved in the analysis ac-
cording to gender, age and BMI to receive the probiotic
or placebo by covariate adaptive randomization [35]. All
investigators were blinded to the treatments. After
4 weeks, subjects were administered with a single dose
of the influenza vaccine (Influvac®sub-unit 2010/2011
season, Abbott Biologicals B.V., lot number 1070166) con-
taining A/California/7/2009 (H1N1), A/Perth/16/2009
(H3N2) and the B/Brisbane/60/2008- like strain by intra-
muscular injection in the deltoid. Vaccination was carried
out by a research nurse in the presence of a qualified clin-
ician (MG). Details of the study schedule and samples col-
lected are detailed in Fig. 6. Compliance was assessed by
counting returned sachets and by copy numbers of B.
longum, assessed by qPCR. None of the subjects in the
young cohort had previously received seasonal influenza
vaccination or swine flu vaccination. Three subjects in the
older cohort had received swine flu vaccination, and forty
subjects had previously been vaccinated for seasonal influ-
enza, of whom 37 had been vaccinated in the 2009/2010
period.
Blood sample processing
For serum, blood was collected into serum separator
tubes and left at room temperature for 30mins to allow
coagulation. Samples were centrifuged at 1300 × g for
10 min and aliquots of serum were collected and stored
at −80 °C prior to analysis.
Hemagglutination inhibition assay
Serum samples (in duplicate) were sent to the Health
Protection Agency (London, UK) for analysis of total
antibody responses to each of the 3 viral subunits. This
Fig. 6 Study design
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technique is based on the ability of specific anti-
influenza antibodies to inhibit hemagglutination of red
blood cells by influenza virus hemagglutinin protein.
Serum antibody titers measured by hemagglutination in-
hibition (HI) assay was performed using an 8-step dilu-
tion protocol (1:8 to 1:1024). Serum samples were
titrated in duplicate, and samples showing titres of 1024
were further titrated up to 1:4096. Titres which were < 8
(below the detection limit) were expressed as 4, to repre-
sent half of the detection threshold. Post-vaccination
antibody titres were not normally distributed, and were
therefore log transformed.
Analysis of vaccine-specific Ig subclasses
Vaccine-specific Ig subclasses were analysed using an in-
house ELISA method. Briefly, 96-well maxisorb ELISA
plates (Serotec) were coated with 500 ng/ml of the vac-
cine (Influvac sub-unit 2010/2011) in coating buffer
(0.5 M Na2CO3). After overnight incubation at 4 °C,
plates were washed three times with wash solution
(50 nM TRIS, 0.14 M NaCl, 1 % BSA, 0.2 % Tween-
20 in dH20). Blocking buffer (5 % BSA in PBS) was
added and plates were incubated for 1 h at 37 °C.
After three washes, plasma samples (neat for IgA,
IgD, IgM, and diluted 1:100 in PBS for IgG1) were
added, and plates were incubated for a further hour
at RT. Plates were then washed to remove non-
specific binding antibodies and mouse anti-human
IgA, IgG, IgM or IgD was added. IgA, IgG1, and IgM
were diluted with PBS 1:1000, whereas IgD was di-
luted 1:500. After a 1 h incubation, diluted horse rad-
ish peroxidase conjugated goat anti-mouse IgG (H/L)
(AbD Serotec, Oxfordshire, UK) was added and the
plate was incubated for a further 1 h at RT. Substrate
(3.3’, 5.5’ tetramethylbenzidine) was added and the re-
action was stopped with 0.16 M sulphuric acid. Plates
were read at 450 nm in a micro-plate autoreader
(Thermo Scientific) and the results were presented as
a mean optical density units (OD) ± SEM.
To minimize inter-assay variation, three quality con-
trol samples were included in every assay, consisting of
post-vaccination plasma samples from two young and
one older subject.
Analysis of salivary sIgA
Saliva samples were collected by passive drooling into
a sterile screw-cap tube, centrifuged at 13,000 × g for
10 min at 4 °C to remove cells and debris and stored
at −80 °C until analysis, which was completed within
6 months. The concentration of sIgA in saliva was ana-
lysed by sandwich ELISA using a commercially available
kit (Immunodiagnostik AG, Bensheim, Germany) in ac-
cordance with the manufacturer’s instructions.
Analysis of anti-CMV IgG antibodies
Concentrations of anti-CMV IgG antibodies were
analysed by ELISA according to the manufacturer’s in-
structions (ab108724 Anti-Cytomegalovirus (CMV) IgG
Human Elisa Kit, Abcam, UK) and read in a microplate
reader (GENios) at 450 nm, with 620 nm as a reference
wavelength.
T cell phenotyping
Peripheral blood mononuclear cells (PBMC: 1 × 106) were
stained with the following fluorochrome-conjugated mono-
clonal antibodies: (PerCP) labelled anti-CD3, (AmCyan)
labelled anti-CD4, (APC-Cy7) labelled anti-CD8, (PE-Cy7)
labelled anti-CD25, (Pacifice Blue) labelled anti-CD28,
(APC) labelled anti-CD57, (FITC) labelled anti-CD26, (PE)
labelled anti-CD127 in TruCOUNT tubes (BD Biosci-
ences), washed and fixed before analysis by multiparamter
flow cytometry (FACS Canto II, BD Biosciences) using BD
FACSDiva™ software.
Relative telomere length
Telomere length of PBMC was measured by using the
DAKO Telomere PNA Kit/FITC for Flow Cytometry
(DAKO, UK), according to the manufacturer’s instruc-
tions. Relative telomere length (RTL) was determined by
comparing isolated PBMC with a control cell line (1301;
subline of the Epstein–Barr virus (EBV) genome nega-
tive T-cell leukaemia line CCRF-CEM; Sigma-Aldrich
Company Ltd, UK). Quantification of RTL was carried
out using an Accuri™ C6 flow cytometer (BD Biosciences,
Oxford, UK).
Quantification of faecal Bifidobacterium longum
Freshly voided faecal samples were collected in sterile
plastic pots and stored at −20 °C.
DNA was extracted from faecal samples using a
commercial kit (Fast DNA Spin kit, MP Biomedicals,
Cambridge, UK) according to the manufacturers’ in-
structions. Quantity and purity of the DNA was
assessed using NanoDrop (Thermo Fisher Scientific
Inc., Loughborough, UK). Real-time quantitative PCR
was performed in triplicate for enumeration of Bifido-
bacterium longum with the Rotor-Gene 6000 (Corbett,
Mortlake, Australia) using 5 μL of extracted faecal
DNA in 20 μL PCR master-mix according to Haarman
and Knol (2005). The reaction was carried out after 1 cycle
at 95 °C for 10 min, followed by 45 cycles at 95 °C × 10,
62 C° per 60 s, 72 °C per 40 s. Standard quantification
was carried out using serially diluted DNA extract of
Bifidobacterium longum bv. infantis CCUG 52,486
strain enumerated by plate count.
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Fluorescence in situ hybridisation
Freshly voided faecal samples were collected in sterile
plastic pots, diluted 1 in 10 (wt:wt) in PBS and homoge-
nised in a Stomacher 400 (Seward, Norfolk, United
Kingdom) for 2 min. A 15 ml sample of faecal slurry was
vortexed with 2 g of 3 mm diameter glass beads and
then centrifuged to remove particulate matter (1500 × g,
2 min). Supernatant was fixed in paraformaldehyde
[1:4 v/v in 4 % PFA in 0.1 mol PBS, pH 7.2] for 4 h at
4 °C, centrifuged (13,000 g 5 mins), washed twice with
0.1 M PBS, resuspended in 1:1 PBS:ethanol and stored
at −20 °C. Oligonucleotide probes used were Cy-3 la-
beled and synthesized by Sigma-Aldrich (Poole, UK).
Probes used were Bif164, Bac303, Chis150, Lab158,
ATO291, Enter1432, Fprau655 and EUB338I/II/III spe-
cific for Bifidobacterium spp., Bacteroides/Prevotella
group, Clostridium clusters I and II (including C. per-
fringens and C. histoliticum), Lactobacillus/Enterococcus
subgroup, Atopobium, Enterobacterium group, Faecali-
bacterium cluster and total bacteria respectively. Samples
were hybridized as described [36]. Data is expressed as
log10 counts per g dry weight faeces.
Self-reported illness
Subjects in the older cohort who received the influenza
vaccination during October/November 2010 in accord-
ance with UK NHS vaccination schedules (n = 43) were
requested to record incidence of any cold or flu like
symptoms in the 6 months post-vaccination. However,
the numbers were too small to be statistically meaning-
ful and are therefore not included.
Statistical analysis
Data were analysed using SPSS software (version 21).
For the primary and continuous secondary endpoints, a
Linear Mixed Model (LMM) was implemented. A first
order autoregressive covariance structure was selected
AR (1), with fixed factors of time (repeated measures),
age and treatment and subject as a random effect. The
main effects are reported first, followed by all two-way
interactions of the variables. Following this initial ana-
lysis, the data were split by cohort (young/older) and the
analysis was repeated in the same manner to determine
time and treatment effects within each cohort. Vaccine-
specific immunoglobulin subclass data were analysed as
change following vaccination. The distribution of the
data was checked using the Kolmogorov-Smirnov test. If
data were not normally distributed, they were log trans-
formed. Antibody titre data were transformed with bin-
ary log (log2n) and were not analysed as change from
baseline. Seroprotection, seroconversion and self-reported
illness data were analysed by the Fisher’s exact test. To ac-
count for multiple primary endpoints, two sided P values
of 0.01 or less were considered statistically significant. All
missing data were classed as missing at random and only
available data were analysed.
Additional files
Additional file 1: Figure S1. Effect of B. longum + Gl-OS on levels of
vaccine-specific IgA, IgG1, IgD and IgM. Data are optical density units
(OD450nm) ± 2 SEM, change from baseline (week 4) for n = 54–58
subjects per group, 2 (week 6) and 4 (week 8) weeks after vaccination.
☐ Maltodextrin, (gray square) B. longum + Gl-OS. Data were analysed
using a Linear Mixed Model (LMM) with fixed factors of time, age and
treatment. For IgA (plot A), there was a significant effect of age (p < 0.001)
and time (p < 0.001) and a significant age*time interaction (p < 0.001). Data
split by cohort showed a significant effect of time in both the young
(p < 0.01) and older (p < 0.001) cohorts. For IgG1 (plot B), there were
significant effects of time (p < 0.001) and age (p < 0.001). Data split by
cohort showed a significant effect of time (p < 0.001) and a trend for
a treatment effect (p= 0.03) in the older cohort, and a significant effect of
time (p< 0.001) in the young cohort. For IgD (plot C), there were significant
effects of age (p< 0.001) and time (p< 0.001) for the combined cohorts and
a significant effect of time in both the young (p< 0.001) and older cohorts
(p < 0.001) when considered separately. For IgM (plot D), there was a
significant effect of time (p < 0.001), but no effect of age or treatment.
(DOCX 52 kb)
Additional file 2: Figure S2. Copy numbers of B. longum + Gl-OS in
faecal samples. Data are mean ± 2SEM for n = 58 young and n = 54 older
subjects. ☐ Maltodextrin, (gray square) B. longum + Gl-OS. Data were
analysed using a Linear Mixed Model (LMM) with fixed factors of time,
age and treatment. There were no statistically significant effects, either
for combined or separate cohorts. (DOCX 25 kb)
Additional file 3: Figure S3. Effect of B. longum + Gl-OS on numbers of
bifidobacteria in seroconverters vs non converters. Data are mean ± 2SEM
for n = 18 seroconverters (to all three subunits) and n = 135 non-converters
in the placebo group and n = 14 seroconverters and n = 36 nonconverters
in the B. longum+ GlOS group. Trend for greater increase in bifidobacteria
in seroconverters compared with non-converters in the B. longum + GlOS
group (p = 0.057). (DOCX 26 kb)
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